FDA Awards Priority Review Voucher to Novartis for Rare Pediatric Disease Product KYMRIAH

Summary

The FDA has issued a priority review voucher to Novartis Pharmaceuticals Corporation for its rare pediatric disease product KYMRIAH, which is manufactured by Novartis Pharmaceuticals Corporation and is used to treat a rare disease.